B7 homolog 3 (B7-H3)
CD276, widely known as B7-H3, is a type I transmembrane glycoprotein and a member of the B7 immune checkpoint ligand superfamily.
CD276, widely known as B7-H3, is a type I transmembrane glycoprotein and a member of the B7 immune checkpoint ligand superfamily. Originally described as a co-stimulatory molecule, B7-H3 has since been characterized as a multifunctional regulator of adaptive immunity with a pronounced role in tumor biology. Structurally, the human isoform exists predominantly in a 4Ig configuration (containing four immunoglobulin-like domains), and its expression pattern is notably tumor-selective: comprehensive bioinformatics and histopathological analyses have confirmed marked upregulation of B7-H3 across a wide spectrum of malignancies, while expression in healthy tissues is also detected in numerous epithelial, endothelial, fibroblast, and osteoblast populations. This differential expression profile has made CD276 one of the most attractive oncological targets under active clinical and preclinical investigation.
At the cellular level, B7-H3 functions as a multifunctional promoter of tumor progression, influencing immune evasion, signal transduction, and metabolic reprogramming within the tumor microenvironment. Recent evidence implicates B7-H3 in exosome biogenesis, suggesting an additional mechanism by which tumor cells exploit this protein to modulate intercellular communication and shape immune resistance. Its interactions with canonical oncogenic pathways — including nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) signaling — as well as the Phosphatidylinositol 3-kinase (PI3K) axis, further underscore its role as a node connecting immune checkpoint function to intracellular proliferative and survival programs. The combination of broad tumor overexpression, low normal-tissue toxicity risk, and mechanistic involvement in immune evasion positions CD276 as a high-priority target for next-generation immunotherapies.
Where the papers sit
16 papers from the last 6 months study B7 homolog 3 (B7-H3) directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 1 observational · 3 human data · 10 preclinical
Themes 3 themes
-
Engineered Cancer Immunotherapy
Engineered immune therapies are moving toward combinations that improve tumor access, persistence and resistance to immune escape. CAR-T and CAR-NK cells are being paired with checkpoint or B7-H3-directed agents, radiopharmaceutical tumor sensitization and tumor-microenvironment remodeling. TIGIT-CD155 signaling and SPARC-dependent CD276 regulation recur as mechanisms that limit immune-cell function. AI-designed minibinders and comparisons of mRNA with yeast display are broadening how cancer-targeting binders are discovered and optimized.
6 papers · 37.5%
-
B7-H3 Targeted Therapy
Antibody-drug conjugates are emerging as the main clinical strategy for B7-H3-positive solid tumors, while CAR-T approaches remain preclinical. YL201 and vobramitamab duocarmazine studies emphasize tumor response alongside cytotoxicity and treatment-related adverse events. Neutrophil-to-lymphocyte ratio and interleukin 6 may help relate baseline inflammation to efficacy and toxicity. Lung cancer dominates, but activity is also being explored in small-cell lung cancer and triple-negative breast cancer.
5 papers · 31.2%
-
B7-H3 Targeting and Imaging
B7-H3 targeting is expanding from target validation into tumor imaging, fluorescence-guided surgery and multivalent drug delivery. 68Ga-labeled bicyclic peptides and antibody-fluorophore conjugates aim to improve lesion detection and surgical localization. Colorectal cancer work links B7H3 with EGFR and c-MET co-expression to guide dual-drug conjugates, while CAR-T cells add EGFR engagers for glioblastoma control. Evidence remains largely preclinical, with clinical translation and target heterogeneity still open.
5 papers · 31.2%
Papers
The 16 papers from the last 6 months that study B7 homolog 3 (B7-H3) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Engineered Cancer Immunotherapy (6)
- Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
- Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy: Elucidating How SPARC Shapes the Tumor Microenvironment and Undermines the Response to Immune Checkpoint Inhibition. Journal of biochemical and molecular toxicology · 26 Aug 2026 PMID 42647088
- AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nature communications · 20 Aug 2026 PMID 42624861
- Enhancing machine learning-based binder design with high-throughput screening: A comparison of mRNA and yeast display technologies. Protein science : a publication of the Protein Society · 10 Jul 2026 PMID 42429042
- GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
- A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
B7-H3 Targeted Therapy (5)
- Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin 6: Analysis of the Phase I/Ib Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714875
- Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
- Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer · 23 Jul 2026 PMID 42487497
- p40-engineered CAR T-cells targeting CD276 enhance anti-tumor efficacy in non-small cell lung cancer. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262195
- "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers. Cancer discovery · 5 Jun 2026 PMID 42249527
B7-H3 Targeting and Imaging (5)
- Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
- B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. Molecular biomedicine · 16 Jun 2026 PMID 42301527
- Fluorescence-Guided Surgery of Rhabdomyosarcoma Using a B7-H3 Targeted Antibody-Fluorophore Conjugate. Molecular pharmaceutics · 11 Jun 2026 PMID 42276839
- Development and Preclinical Evaluation of 68Ga-Labeled B7-H3-Specific Bicyclic Peptides as Immuno-PET Tracers for Oncology. Journal of medicinal chemistry · 9 Jun 2026 PMID 42263262
- B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer. Endocrine-related cancer · 2 Jun 2026 PMID 42227355
By study type
Clinical trials (2)
- Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin 6: Analysis of the Phase I/Ib Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714875
- Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer · 23 Jul 2026 PMID 42487497
Observational studies and case reports (1)
- B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer. Endocrine-related cancer · 2 Jun 2026 PMID 42227355
Human data, design not indexed (3)
- Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
- Enhancing machine learning-based binder design with high-throughput screening: A comparison of mRNA and yeast display technologies. Protein science : a publication of the Protein Society · 10 Jul 2026 PMID 42429042
- "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers. Cancer discovery · 5 Jun 2026 PMID 42249527
Preclinical: animal, cell and lab studies (10)
- Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
- Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy: Elucidating How SPARC Shapes the Tumor Microenvironment and Undermines the Response to Immune Checkpoint Inhibition. Journal of biochemical and molecular toxicology · 26 Aug 2026 PMID 42647088
- AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nature communications · 20 Aug 2026 PMID 42624861
- Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
- GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
- A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
- B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. Molecular biomedicine · 16 Jun 2026 PMID 42301527
- Fluorescence-Guided Surgery of Rhabdomyosarcoma Using a B7-H3 Targeted Antibody-Fluorophore Conjugate. Molecular pharmaceutics · 11 Jun 2026 PMID 42276839
- Development and Preclinical Evaluation of 68Ga-Labeled B7-H3-Specific Bicyclic Peptides as Immuno-PET Tracers for Oncology. Journal of medicinal chemistry · 9 Jun 2026 PMID 42263262
- p40-engineered CAR T-cells targeting CD276 enhance anti-tumor efficacy in non-small cell lung cancer. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262195
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-09-19 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.